Mineralys Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Mineralys Therapeutics, Inc. carries a market capitalization of 1.91B, placing it among publicly traded companies globally.
| Market Cap | 1.91B |
| Enterprise Value | N/A |
Share Statistics
Mineralys Therapeutics, Inc. currently has 82.45M shares outstanding.
| Shares Outstanding | 82.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -4.08 |
| P/TBV Ratio | 3.18 |
| P/FCF Ratio | -14.87 |
| P/OCF Ratio | -14.87 |
Financial Position
Mineralys Therapeutics, Inc. maintains a current ratio of 44.33, meaning it holds 44.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 44.33 |
| Quick Ratio | 43.90 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -30.12 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Mineralys Therapeutics, Inc.'s stock has gained approximately 78.30655% over the past 52 weeks. The 50-day moving average sits at 27.94, while the 200-day moving average is 32.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | 78.30655% |
| 50-Day Moving Average | 27.94 |
| 200-Day Moving Average | 32.61 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -171.45M, while operating income came in at -171.50M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -171.50M |
| Pretax Income | -151.78M |
| Net Income | -151.78M |
| EBITDA | -171.45M |
| EBIT | -171.50M |
| Earnings Per Share (EPS) | -2.03 |
Balance Sheet
Total book value stands at -496.50M, with working capital of 637.75M providing operational flexibility.
| Cash & Cash Equivalents | 646.06M |
| Total Debt | N/A |
| Net Debt | -112.78M |
| Equity (Book Value) | -496.50M |
| Book Value Per Share | -6.63 |
| Working Capital | 637.75M |
Cash Flow
Mineralys Therapeutics, Inc. produced -136.40M in operating cash flow over the past twelve months. After subtracting -15,000.00 in capital expenditures, free cash flow totaled -136.41M - equivalent to -1.82 per share.
| Operating Cash Flow | -136.40M |
| Capital Expenditures | -15,000.00 |
| Free Cash Flow | -136.41M |
| FCF Per Share | -1.82 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -21.01 |
| FCF Yield | -6.73 |
Scores
Mineralys Therapeutics, Inc. posts an Altman Z-Score of 81.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 81.91 |